Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Operating Leases (2019 - 2025)

Intellia Therapeutics (NTLA) has disclosed Operating Leases for 7 consecutive years, with $66.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Leases fell 64.81% to $66.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $66.8 million, a 64.81% decrease, with the full-year FY2025 number at $66.8 million, down 64.81% from a year prior.
  • Operating Leases was $66.8 million for Q4 2025 at Intellia Therapeutics, down from $70.6 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $190.0 million in Q4 2024 to a low of $34.8 million in Q1 2021.
  • A 5-year average of $85.5 million and a median of $81.5 million in 2024 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: soared 376.71% in 2021, then tumbled 64.81% in 2025.
  • Intellia Therapeutics' Operating Leases stood at $64.9 million in 2021, then soared by 75.65% to $114.0 million in 2022, then dropped by 15.15% to $96.7 million in 2023, then surged by 96.34% to $190.0 million in 2024, then crashed by 64.81% to $66.8 million in 2025.
  • Per Business Quant, the three most recent readings for NTLA's Operating Leases are $66.8 million (Q4 2025), $70.6 million (Q3 2025), and $75.6 million (Q2 2025).